Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Citigroup Inc.    C

CITIGROUP INC.

(C)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Citi : Appointed as Depositary Bank for Stealth BioTherapeutics' ADR Programme

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/21/2019 | 07:47am EDT

Citi, acting through Citibank N.A., has been appointed by Stealth BioTherapeutics Corp. (“Stealth”) as depositary bank for its American Depositary Receipt (“ADR”) programme. Stealth’s ADRs trade on the Nasdaq Global Market under the symbol “MITO.” Each ADR represents 12 ordinary shares of Stealth.

“We are pleased to have been selected by Stealth as depositary bank for its Nasdaq listed ADR programme,” said Dirk Jones, Global Head of Issuer Services, at Citi. “We look forward to supporting the expansion of Stealth’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”

For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

About Stealth BioTherapeutics

Stealth BioTherapeutics (“Stealth”) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. Stealth believes their lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases. Stealth is studying elamipretide in the following primary mitochondrial diseases: primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy. The company is also studying elamipretide in dry age-related macular degeneration. Stealth’s other pipeline candidates include SBT-20, which is being evaluated for rare peripheral neuropathies, and SBT-272, which is being evaluated for rare neurodegenerative disease indications. The company has optimized its discovery platform to identify novel mitochondrial-targeted compounds, which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria. Stealth’s mission is to be the leader in mitochondrial medicine, and the company has assembled a highly experienced management team, board of directors and group of scientific advisors to help them achieve this mission.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CITIGROUP INC.
07/19AmEx warns of higher costs as it boosts rewards program, shares fall
RE
07/19Microsoft Showing DJIA's Second-Largest Gains Friday
DJ
07/19Morgan Stanley Profit Falls as Trading Slows -- WSJ
DJ
07/18Goldman Sachs' equities-backed earnings results may face pressure
RE
07/18CITIGROUP : Raises Quarterly Dividend by 13.3% to 51 Cents
DJ
07/18CITIGROUP : Declares Common Stock Dividend; Citigroup Declares Preferred Dividen..
BU
07/18Consumers Lift Bank of America Profit -- WSJ
DJ
07/17BRIAN MOYNIHAN : Bank of America trims net interest income guidance
RE
07/17Trade, earnings worry drag on stocks; U.S. Treasury yields fall
RE
07/17Trade, earnings worry drag on global stocks; U.S. Treasury yields fall
RE
More news
Financials (USD)
Sales 2019 73 951 M
EBIT 2019 31 395 M
Net income 2019 17 216 M
Debt 2019 -
Yield 2019 2,70%
P/E ratio 2019 9,32x
P/E ratio 2020 8,40x
Capi. / Sales2019 2,17x
Capi. / Sales2020 2,12x
Capitalization 161 B
Chart CITIGROUP INC.
Duration : Period :
Citigroup Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CITIGROUP INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,60  $
Last Close Price 71,11  $
Spread / Highest target 51,9%
Spread / Average Target 13,3%
Spread / Lowest Target -26,9%
EPS Revisions
Managers
NameTitle
Michael Louis Corbat Chief Executive Officer & Director
James Anthony Forese President & CEO-Institutional Clients Group
John C. Dugan Chairman
John C. Gerspach Chief Financial Officer
Anthony M. Santomero Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CITIGROUP INC.36.59%160 645
JP MORGAN CHASE & COMPANY16.31%370 635
INDUSTRIAL AND COMMERCIAL BANK OF CHINA5.86%282 113
BANK OF AMERICA19.32%276 261
WELLS FARGO & COMPANY0.87%205 423
CHINA CONSTRUCTION BANK CORPORATION13.81%199 692